| Ytd | -14.66% | |
| 1y | -21.05% |
| Open | 5.00 | Prev Close | 4.99 | Low | 4.85 | High | 5.04 | Mkt Cap | 116.12M |
| Vol | 151.83K | Avg Vol | 158.05K | EPS | -1.06 | P/E | N/A | Forward P/E | -4.25 |
| Beta | 0.58 | Short Ratio | 1.53 | Inst. Own | 19.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 4.75 | 200-d Avg | 4.73 | 1yr Est | 15.50 |
COYA News
120th participant has been enrolled in ALSTARS trial achieving target enrollmentAdditional eligible
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
BTIG analyst Thomas Shrader reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietar
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ:COYA) with a Buy
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analys
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to th
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-st
Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-st
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONT
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
On May 12, 2026, Coya Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analys
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus ra
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results befo
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimi
Coya Therapeutics is working On neurodegenerative disease treatment with its combination therapies t
During Monday's session, 201 stocks hit new 52-week lows.
During Friday, 24 stocks hit new 52-week lows.